GRI Bio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.53 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.34M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Details
| Name | GRI Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 4 |
| Founded | 2018 |
| Ceo | W. Hertz |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US3622AW5029 |
| Cusip | 3622AW502 |
| Cik | 0001824293 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. W. Marc Hertz Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Vipin Kumar Chaturvedi Ph.D. | Co-Founder and Chief Scientific Officer |
| Leanne M. Kelly | Chief Financial Officer and Corporate Secretary |
| Dr. Albert Agro Ph.D. | Co-Founder and Chief Medical Officer |
Contact
| Address | 2223 Avenida de la Playa, Suite 208, La Jolla, California 92037, United States |
| Phone | 619 400 1170 |
| Website | https://www.gribio.com |